Analytical Data
-
Gene name
CHD1L
- Application
-
Alternative Names
Amplified in liver cancer protein 1
-
Species
Human
-
Source
E. coli
-
Tag
N- His-SUMO
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q86WJ1
-
Expression Region
704-897aa
-
Molecular Weight
37.3 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
CHD1L (Chromodomain Helicase DNA Binding Protein 1-Like) is a member of the CHD (Chromodomain Helicase DNA-binding) family of proteins, which play crucial roles in chromatin remodeling, gene expression regulation, and DNA repair processes. Recent studies have highlighted the importance of CHD1L in various cellular functions, including cell growth, differentiation, and response to DNA damage. Dysregulation of CHD1L has been implicated in several cancers, making it a potential target for therapeutic intervention. The study of recombinant CHD1L proteins enables researchers to delve into its molecular mechanisms, assess its interaction with other cellular components, and evaluate its potential as a biomarker or therapeutic target. Furthermore, understanding the structural and functional characteristics of CHD1L could provide insights into the development of innovative cancer treatments and enhance our knowledge of the molecular pathways involved in tumorigenesis. Therefore, exploring recombinant CHD1L presents a promising avenue for advancing cancer biology and personalized medicine approaches.
